A

ANI Pharmaceuticals
D

ANIP

53.420
USD
-0.85
(-1.57%)
مغلق
حجم التداول
13,762
الربح لكل سهم
4
العائد الربحي
-
P/E
-114
حجم السوق
1,122,769,541
أصول ذات صلة
    C
    CAH
    1.290
    (1.10%)
    118.260 USD
    H
    HSIC
    0.860
    (1.25%)
    69.790 USD
    I
    ICLR
    3.020
    (1.48%)
    207.680 USD
    IDXX
    IDXX
    3.66
    (0.90%)
    412.45 USD
    L
    LH
    1.670
    (0.74%)
    228.660 USD
    P
    PAHC
    0.035
    (0.16%)
    21.715 USD
    P
    PETQ
    0.000
    (0.00%)
    30.990 USD
    P
    PRGO
    0.060
    (0.23%)
    25.770 USD
    ZBH
    ZBH
    1.260
    (1.19%)
    107.050 USD
    ZTS
    ZTS
    1.280
    (0.78%)
    164.750 USD
    المزيد
الأخبار

العنوان: ANI Pharmaceuticals

القطاع: Healthcare
الصناعة: Drug Manufacturers - Specialty & Generic
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.